LONDON, United Kingdom, July 13, 2026
The Alzheimer’s Association has announced the launch of the PROTECT-Cog Study (Prevention of Risk fOr cogniTive dEcline through Combined Therapy), a groundbreaking global clinical trial designed to determine whether combining a proven multidomain lifestyle intervention with a GLP-1 receptor agonist or similar metabolism-targeting therapy can further reduce the risk of cognitive decline, mild cognitive impairment (MCI), and dementia in older adults at elevated risk. Unveiled during the Alzheimer’s Association International Conference (AAIC®) 2026 in London, the $100 million initiative represents one of the largest and most ambitious dementia prevention studies ever undertaken. Building upon the success of the U.S. POINTER and LatAm FINGERS studies, PROTECT-Cog seeks to evaluate whether combining evidence-based lifestyle modification with emerging pharmacological approaches can deliver greater protection against Alzheimer’s disease and related dementias before clinical symptoms appear. The study reflects the growing global focus on preventive medicine, precision healthcare, and multimodal interventions designed to delay or prevent neurodegenerative disease progression.
Global Clinical Trial Combines Lifestyle Intervention with GLP-1 Therapy
The PROTECT-Cog Study will enroll older adults who are at increased risk for cognitive decline and compare two structured lifestyle intervention strategies while simultaneously evaluating the addition of a GLP-1 receptor agonist or similar metabolism-targeting drug. Participants will receive either an intensive coaching-based multidomain lifestyle program or a structured program with fewer participant interactions while researchers assess cognitive performance, overall health, frailty, quality of life, and progression toward mild cognitive impairment over a three-year follow-up period. Comprehensive clinical and cognitive assessments will be performed every six months, allowing investigators to identify which combination of interventions provides the greatest protection against age-related cognitive decline. The innovative study design reflects increasing scientific interest in combining behavioral risk reduction strategies with pharmacological therapies to address multiple biological pathways involved in Alzheimer’s disease development.
Building on Strong Evidence for Dementia Risk Reduction
The launch of PROTECT-Cog follows encouraging findings from the U.S. POINTER trial, which demonstrated that participants following a structured multidomain lifestyle program achieved significantly greater cognitive benefits than those using self-guided interventions. Those improvements were equivalent to approximately one to two years of cognitive advantage, while also reducing frailty, improving sleep apnea, and supporting healthier blood pressure regulation. At the same time, growing real-world evidence suggests that GLP-1 receptor agonists may reduce dementia risk by 40% to 70% compared with other diabetes treatments, particularly among individuals with obesity or elevated body mass index. Experimental research further indicates these therapies may influence brain inflammation, metabolic regulation, and vascular health, making them promising candidates for dementia prevention. PROTECT-Cog is expected to generate important clinical evidence clarifying whether combining these complementary interventions provides superior protection against Alzheimer’s disease and related neurodegenerative disorders.
Advertisement
Advancing Precision Prevention for Alzheimer’s Disease
The initiative reinforces the Alzheimer’s Association’s leadership in global dementia prevention research through its expanding portfolio of large-scale collaborative studies. Supported by international research infrastructure established through U.S. POINTER, LatAm FINGERS, and the World-Wide FINGERS Network, PROTECT-Cog aims to accelerate scientific understanding of personalized prevention strategies that combine lifestyle modification, metabolic therapies, and precision medicine approaches. Researchers also expect the trial to provide valuable insights into disease mechanisms, intervention timing, and patient populations most likely to benefit from combined therapeutic strategies. As Alzheimer’s disease continues to impose a growing healthcare burden worldwide, the results from PROTECT-Cog may help shape future prevention guidelines, influence clinical practice, and support the development of integrated treatment strategies capable of delaying cognitive decline before irreversible neurological damage occurs, ultimately improving long-term patient outcomes and quality of life.
Source: Alzheimer’s Association press release
